Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. [electronic resource]
Producer: 20030912Description: 49-58 p. digitalISSN:- 1474-0338
- Abciximab
- Acetates -- economics
- Acute Disease
- Antibodies, Monoclonal -- economics
- Coronary Disease -- drug therapy
- Drug Evaluation
- Eptifibatide
- Guidelines as Topic
- Humans
- Immunoglobulin Fab Fragments -- economics
- Incidence
- Injections, Intravenous
- Peptides -- economics
- Platelet Aggregation Inhibitors -- economics
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Risk Assessment
- Tirofiban
- Treatment Outcome
- Tyrosine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.